Oxycodone And Aspirin Tablet
NDC Package 42806-061-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Oxycodone And Aspirin tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. This formulation utilizes a tablet delivery system. Marketed by Epic Pharma, Llc, this product is identified by NDC 42806-061 and is authorized under FDA application ANDA040910.

Identification & Billing

NDC Package Code
42806-061-01
Package Description
100 TABLET in 1 BOTTLE
Product Code
42806-061
11-Digit Billing Format
42806006101
RxNorm Crosswalk
  • RxCUI: 848768 - oxyCODONE 4.8355 MG / aspirin 325 MG Oral Tablet
  • RxCUI: 848768 - aspirin 325 MG / oxycodone hydrochloride 4.84 MG Oral Tablet
  • RxCUI: 848768 - ASA 325 MG / oxycodone hydrochloride 4.8355 MG Oral Tablet
  • RxCUI: 848768 - ASA 325 MG / oxycodone hydrochloride 4.84 MG Oral Tablet

Clinical Specifications

Proprietary Name
Oxycodone And Aspirin
Non-Proprietary Name
Oxycodone And Aspirin
Substance Name
Aspirin; Oxycodone Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Oxycodone and aspirin tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses (see WARNINGS), reserve oxycodone and aspirin tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics) •Have not been tolerated, or are not expected to be tolerated, •Have not provided adequate analgesia, or are not expected to provide adequate analgesia
DEA Schedule
Schedule II (CII) Substances

Regulatory & Marketing

Labeler Name
Epic Pharma, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA040910
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-30-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 42806-061-01 identifies a specific commercial package of 100 tablet in 1 bottle of Oxycodone And Aspirin, a human prescription drug labeled by Epic Pharma, Llc. This tablet is formulated for oral use and contains aspirin; oxycodone hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Epic Pharma, Llc on June 30, 2020. The current certification is valid through December 31, 2026.

How is this Epic Pharma, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 42806006101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
42806-061-01
11-Digit CMS (5-4-2)
42806-0061-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.